Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide

Shannon R. McCurdy(Hospital of the University of Pennsylvania), Yvette L. Kasamon(Johns Hopkins University), Gary L. Rosner(Johns Hopkins University), Heather J. Symons(Johns Hopkins University), B. Douglas Smith(Johns Hopkins University), Leo Luznik(Johns Hopkins University), William Matsui(The University of Texas at Austin), Ivan Borrello(Tampa General Hospital), Amy E. DeZern(Johns Hopkins University), Karlo Perica(Memorial Sloan Kettering Cancer Center), Richard J. Jones(Sidney Kimmel Comprehensive Cancer Center), Jennifer A. Kanakry(National Institutes of Health), Keith W. Pratz(University of Pennsylvania), Ivana Gojo(Johns Hopkins University), Ephraim J. Fuchs(Johns Hopkins University), Richard F. Ambinder(Johns Hopkins University), Gabrielle T. Prince(Johns Hopkins University), Michael A. McDevitt(University of Colorado Boulder), Christopher G. Kanakry(National Cancer Institute), Robert A. Brodsky(Johns Hopkins University), Carol Ann Huff(Sidney Kimmel Comprehensive Cancer Center), Mark J. Levis(Sidney Kimmel Cancer Center), Margaret M. Showel(Johns Hopkins University), Hua-Ling Tsai(Johns Hopkins University), Douglas E. Gladstone(Northwell Health), Lode J. Swinnen(Johns Hopkins University), Javier Bolaños‐Meade(Johns Hopkins University)
Blood
March 27, 2015
Cited by 299


Related Papers